Z
7.32
-0.17 (-2.27%)
| Previous Close | 7.49 |
| Open | 7.63 |
| Volume | 398,558 |
| Avg. Volume (3M) | 431,388 |
| Market Cap | 396,128,384 |
| Price / Sales | 14.66 |
| Price / Book | 10.21 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Operating Margin (TTM) | -128.01% |
| Diluted EPS (TTM) | -2.28 |
| Quarterly Revenue Growth (YOY) | -6.80% |
| Total Debt/Equity (MRQ) | 152.01% |
| Current Ratio (MRQ) | 2.53 |
| Operating Cash Flow (TTM) | -69.67 M |
| Levered Free Cash Flow (TTM) | -36.36 M |
| Return on Assets (TTM) | -31.03% |
| Return on Equity (TTM) | -207.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zevra Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 5.0 |
| Insider Activity | 3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -3.5 |
| Average | 1.30 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.85% |
| % Held by Institutions | 62.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Retirement Planning Co Of New England, Inc. | 31 Dec 2024 | 514,832 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Canaccord Genuity, 241.53%) | Buy |
| 25.00 (Cantor Fitzgerald, 241.53%) | Buy | |
| Median | 22.00 (200.55%) | |
| Low | 18.00 (Citizens Capital Markets, 145.90%) | Buy |
| Average | 22.00 (200.55%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 7.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 13 Mar 2025 | 25.00 (241.53%) | Buy | 7.94 |
| Guggenheim | 13 Mar 2025 | 22.00 (200.55%) | Buy | 7.94 |
| HC Wainwright & Co. | 13 Mar 2025 | 20.00 (173.22%) | Buy | 7.94 |
| Cantor Fitzgerald | 12 Mar 2025 | 25.00 (241.53%) | Buy | 7.92 |
| Citizens Capital Markets | 12 Mar 2025 | 18.00 (145.90%) | Buy | 7.92 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Mar 2025 | Announcement | Zevra Therapeutics Files Preliminary Proxy |
| 11 Mar 2025 | Announcement | Zevra Reports Full Year 2024 and Fourth Quarter Financial Results |
| 28 Feb 2025 | Announcement | Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C |
| 27 Feb 2025 | Announcement | Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million |
| 26 Feb 2025 | Announcement | Zevra to Report 2024 Fourth Quarter and Full Year Financial Results |
| 24 Feb 2025 | Announcement | Zevra to Participate at Upcoming Investor Conferences |
| 30 Jan 2025 | Announcement | Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ |
| 29 Jan 2025 | Announcement | Zevra Therapeutics to Participate at Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |